Skip to content

Study · Non-randomized trial · n = 41 · 2015

3 results

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M

Journal of pharmacokinetics and pharmacodynamics21 Apr 2015Cited by 1 (Europe PMC)

PMID25895899 (opens in a new tab)DOI10.1007/s10928-015-9416-2 (opens in a new tab)PepBankPUB-25895899
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In HIV-infected patients and healthy volunteers, the sequential PK/PD model predicted the time course of GH after multiple tesamorelin doses well.

    In plain wordsIn HIV-infected patients and healthy volunteers, a model predicted well how growth hormone levels changed over time after repeated tesamorelin doses.

    Peptide
    Tesamorelin
    Outcome
    Not applicableGH time course prediction by PK/PD model
    Study

    n = 41

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 or 2 mg · subcutaneous · 14 daysAs given in this study (human).

    Source sentences

    Summary
    The time course of GH and IGF-1 concentrations following multiple doses of tesamorelin were well predicted
    1 context sentence
    Summary · context
    A total of 41 subjects in Phase I trials receiving subcutaneous daily doses of 1 or 2 mg of tesamorelin during 14 consecutive days were included in this analysis.
  2. 02HumanNon-randomized trialActivity measurement

    In HIV-infected patients and healthy volunteers, the sequential PK/PD model predicted the time course of IGF-1 after multiple tesamorelin doses well.

    In plain wordsIn HIV-infected patients and healthy volunteers, a model predicted well how IGF-1 levels changed over time after repeated tesamorelin doses.

    Peptide
    Tesamorelin
    Outcome
    Not applicableIGF-1 time course prediction by PK/PD model
    Study

    n = 41

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 or 2 mg · subcutaneous · 14 daysAs given in this study (human).

    Source sentences

    Summary
    The time course of GH and IGF-1 concentrations following multiple doses of tesamorelin were well predicted
    1 context sentence
    Summary · context
    A total of 41 subjects in Phase I trials receiving subcutaneous daily doses of 1 or 2 mg of tesamorelin during 14 consecutive days were included in this analysis.
  3. 03HumanNon-randomized trialActivity measurement

    In HIV-infected patients and healthy volunteers, no covariate (age, weight, BMI, sex, race, health status) was significantly associated with the GH or IGF-1 model parameters.

    In plain wordsIn HIV-infected patients and healthy volunteers, age, weight, sex, race and health status did not significantly affect the modelled growth hormone and IGF-1 response.

    Peptide
    Tesamorelin
    Outcome
    No significant changeCovariate effects on GH and IGF-1 model parameters
    Study

    n = 41

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 or 2 mg · subcutaneous · 14 daysAs given in this study (human).

    Source sentences

    Summary
    Within the range of the values evaluated no covariates were significantly associated with GH or IGF-1 model parameters.
    2 context sentences
    Summary · context
    The effect of age, body weight, body mass index, sex, race, and health status on the model parameters was evaluated.
    Summary · context
    A total of 41 subjects in Phase I trials receiving subcutaneous daily doses of 1 or 2 mg of tesamorelin during 14 consecutive days were included in this analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.